Pharmaceuticals

Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries

SHANGHAI and MOSCOW, Dec. 20, 2022 /PRNewswire/ -- Mabwell Bioscience (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, today announced the company has entered into an licensing agreement with the Russian pharmaceutical company Binnopharm Group, for 9M...

2022-12-20 17:00 1315

SeekIn Receives CE-IVD Mark Approval for PanCanSeek® Cancer Mutation Detection Kit

First-of-its-kind one-for-all cancer mutation detection test SHENZHEN, China, Dec. 19, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for PanCanSeek® Cancer Mutation Detection Kit...

2022-12-19 21:00 1102

Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON

WUHAN, China and SAN DIEGO, Dec. 19, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth")today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application on the in-vivo gene replacement therapy NFS-02 (rAAV2-ND1), for the...

2022-12-19 21:00 1180

GenFleet Therapeutics and Merck Enter into Trial Collaboration to Initiate Study Investigating Combination Therapy of GFH925 (KRAS G12C inhibitor) and ERBITUX® (cetuximab)

SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck to start a clinical study of...

2022-12-19 19:00 922

TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody

HEFEI, China, Dec. 17, 2022 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (Hefei, China), an innovative biotech company dedicated to the discovery of novel immunotherapeutic drugs and a leader in NK cell research globally, today announced that the U.S. Food and Drug Administration (FDA) has cleared i...

2022-12-17 21:30 2455

Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer

HANGZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Hangzhou, Zhejiang, China, [ December 9th, 2022], Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered ...

2022-12-16 09:00 1180

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd. has been removed from the Unverified List (UVL) by the U.S. Depar...

2022-12-16 08:44 1257

China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19

HAIKOU, China, Dec. 15, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced that its drugs were listed in The...

2022-12-15 21:00 1088

Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial

Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1]  which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamem® may assist where treatment by anti-depressant medication alone is inadequate SYDNEY, Dec. 14, 2...

2022-12-14 21:52 1279

E-Home Household Services Holdings Limited's subsidiary Zhong Run Launches Cloud Pharmacy Service to Address New Situation of Epidemic Prevention and Control

FUZHOU, China, Dec. 14, 2022 /PRNewswire/ -- E-Home Household Service Holdings Limited (Nasdaq: EJH) (the "Company" or "E-Home"), a provider of integrated household services inChina, today announced that the Company's subsidiary Zhongrun (Fujian) Pharmaceutical Co., Ltd. ("Zhongrun") plan to expa...

2022-12-14 21:30 2094

Hovione and GEA announce a strategic collaboration to advance Continuous Tableting

LISBON, Portugal, Dec. 14, 2022 /PRNewswire/ -- Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA´s engineering expertise with Hovione´s devel...

2022-12-14 21:00 1261

Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022

GERMANTOWN, Md. and HONG KONG, Dec. 13, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...

2022-12-14 01:40 1521

Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates

Collaboration to explore potential of creating next-generation antibody-drug conjugateswith Biosion's SynTracer® internalization platform and ImmunoGen's proprietary linker-payload technology NEWARK, Del., Dec. 13, 2022 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology comp...

2022-12-13 18:00 1374

Live from ASH 2022 | Ascentage Pharma Presents Latest Data of APG-2575, Including Encouraging Results of the Combination with BTKi in Patients with R/R CLL/SLL

SUZHOU, China and ROCKVILLE, Md. , Dec. 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released preliminary results from a ...

2022-12-13 17:39 1257

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatat the 2022 American Society of Hematology (the "ASH") Annual Mee...

2022-12-12 21:50 1664

FDA clears RF Medical's MYGEN™ M-3004 and MYOBLATE™ Radiofrequency Ablation System

SEOUL, South Korea, Dec. 12, 2022 /PRNewswire/ -- RF Medical Co., Ltd. is a premier Korean-based medical company serving the healthcare industry for almost two decades. Recently, FDA cleared RF Medical's patented MYGEN™ M-3004 generator and MYOBLATE™ radiofrequency ablation system.

2022-12-12 21:23 1015

PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)

DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co...

2022-12-12 21:00 1240

Asieris'Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Hexvix®, a drug used for bladder c...

2022-12-12 20:59 1082

Asieris Enrolled First Patient for its Phase II Clinical Study of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the first patient enrolled in phas...

2022-12-12 17:47 1043

SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France

Cenobamate (ONTOZRY®), for the treatment of uncontrolled focal-onset seizures in adults, is now available in 5 major European countries –Germany, the UK, Italy, Spain, France – and 10 other key markets PANGYO, South Korea, Dec. 8, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global ...

2022-12-09 06:30 1514
1234567 ... 84